title: [Diagnosis, treatment and results of malignant skull base tumours].
abstract: BACKGROUND
  Malignant tumours of the cranial base are rare and present usually in advanced tumour stage due to the lack of early clinical symptoms.
  
  
  METHODS
  Sixty patients with malignant tumours infiltrating the skull base were treated at the Department of Otorhinolaryngology Head and Neck Surgery, University of Würzburg between 1987 and 1999. Most of the tumours (n = 51) originated from the nose or paranasal sinuses, the epipharynx, the outer ear canal or the middle ear. Seven tumours were malignant brain tumours infiltrating the bony structures of the skull base or originated from the cranial base itself. Two patients suffered from metastases of an adenocarcinoma of the prostata. The histological diagnosis was confirmed in 53 patients preoperatively and in seven patients during tumour resection. Squamous cell carcinoma (n = 24), adenocarcinoma (n = 10) and sarcoma (n = 7) were the most common histologies found.
  
  
  RESULTS
  A radical en bloc resection of the tumour was only possible in 26 out of 60 cases. A surgical tumour reduction with postoperative radiation therapy was performed in seven patients as a palliative approach. Eight patients underwent a combined radio- and chemotherapy according to the histological diagnosis. Primary radiotherapy was the treatment of choice in eleven patients, where the tumours were located in the central area of the cranial base. Palliative radiotherapy or solely medical pain control were applied to eight patients who presented either with distant metastases or an advanced tumour growth. The mean postoperative survival following radical surgery was 48 months and after primary radiotherapy 27 months.
  
  
  CONCLUSIONS
  A statistical analysis of the results is not applicable due to the great variety of the disease concerning the histological diagnosis, the tumour size and the location as well as the small number of patients.
authors.affiliation: Univ.-HNO-Klinik Würzburg, Germany. c.voelter@mail.uni-wuerzburg.de
authors.forename: C
authors.initials: C
authors.lastname: Völter
authors.forename: G
authors.initials: G
authors.lastname: Baier
authors.forename: F
authors.initials: F
authors.lastname: Hoppe
authors.forename: K
authors.initials: K
authors.lastname: Schwager
authors.forename: J
authors.initials: J
authors.lastname: Helms
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D018304:Esthesioneuroblastoma, Olfactory / Q000175:diagnosis / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D011183:Postoperative Complications; D012509:Sarcoma / Q000175:diagnosis / Q000628:therapy; D019292:Skull Base Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents